ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GDR Genedrive Plc

1.625
0.025 (1.56%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 1.56% 1.625 1.60 1.65 1.675 1.60 1.60 11,401,604 10:40:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0447 -0.36 1.87M
Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 1.60p. Over the last year, Genedrive shares have traded in a share price range of 1.425p to 20.75p.

Genedrive currently has 115,139,946 shares in issue. The market capitalisation of Genedrive is £1.87 million. Genedrive has a price to earnings ratio (PE ratio) of -0.36.

Genedrive Share Discussion Threads

Showing 6651 to 6674 of 26350 messages
Chat Pages: Latest  274  273  272  271  270  269  268  267  266  265  264  263  Older
DateSubjectAuthorDiscuss
11/2/2021
09:06
oilisgold10 Feb '21 - 16:27 - 4603 of 4654
0 0 0
Your non stop rubbish is causing new Lambs to make no money, FCA you been reported to as well.
oilisgold10 Feb '21 - 16:28 - 4604 of 4654
0 0 0
There is a limit to how much rubbish and garbage you post each day saying the same
———;
IConcur pmsl

andymunchkin
11/2/2021
09:00
50,000 share buy ,
bunz3
11/2/2021
08:44
think AVCT is the next to blow big time. Switching from here with profits into AVCT seems a good move. Never fall in love with a stock. This has seen such a big rise.....
onehanded
11/2/2021
08:42
Show us your reading skills by copy and pasting the extract from an RNS that says that.
iman1974
11/2/2021
08:38
looking like more buyers getting back in again
bunz3
11/2/2021
08:35
Wow swinging a lot today
pal44
11/2/2021
08:10
strong start ,like this buying .
bunz3
11/2/2021
08:04
nice buying ,good start ,

oilisgold ,stop making things up and trying to mislead

bunz3
11/2/2021
07:46
Good summary Amigo! U are devious, evil and thick; they are key buzz redeeming features for you......
professor_az
11/2/2021
07:42
just filter it RV2, less people comment on the garbage, sooner he goes.
stoxx67
11/2/2021
07:39
Totally agree with that ...ADVFN is full of themWorking for the MM ..... boiler rooms
amaretto1
11/2/2021
07:08
You are one sick individual !!
amaretto1
11/2/2021
07:03
Oilisgold is desperate...and blatantly misleading. I don't know where he got that announcement.

This was the trading update last July:

"Year-end Trading Update
Revenue for the 12 month period to 30 June 2020 was GBP1.0m, in line with market expectations but below the same period in the prior year (2019: GBP2.4m) owing, as previously announced, to the significant impact of COVID-19 on the Company's pre-existing business activities. The Company ended the financial year with a much stronger balance sheet and is well-funded to execute on new opportunities in Coronavirus testing as well as the wider product development pipeline. The Company closed the year with cash balances of GBP8.2m (31 December 2019: GBP3.5m) after the successful fundraise in May 2020. Following the conversion of the US$8.0m GHIF bond on 16 June 2020 the Company has also significantly reduced the level of debt on the balance sheet."


And from November Final Results:

"Year-end cash of GBP8.2m (Dec 2019: GBP3.5m) following a successful equity fundraise in May 2020"

aquilla
11/2/2021
06:41
Raise adfitional funds, its all in the RNS.
oilisgold
11/2/2021
06:40
Going concern

We have experienced delays commercialising the Genedrive® 96 SARS CoV-2 test and the lack of revenue has impacted our cash position. However we continue to focus on obtaining product approvals and securing sales and we are managing the cost base until revenues are assured. We are confident in our sales forecasts but securing cash generative revenue in the forthcoming months is necessary otherwise the Group will haveto reduce costs and raise additional funds. We continue to adopt a going concern basis for the preparation of the accounts, but the combination of the above factors represents a material uncertainty that may cast significant doubt on the Group and Company's ability to continue as a going concern.

oilisgold
11/2/2021
06:40
Jam, did you not read the RNS?
oilisgold
11/2/2021
06:40
Bunz Aka Sharehunter , everyone knows is a paid RAMPER
oilisgold
11/2/2021
06:40
blah blah blah no, you are the going concern you twit...you sound so desperate. Don't tell me you have got a short on here?
jambam
11/2/2021
06:39
Same as last time. Will be pumped to 300p then the dump again
oilisgold
11/2/2021
06:38
That was from Nov RNS, the Rampers have got rose tinted specs on
oilisgold
11/2/2021
06:38
Looks like placing on the way to me.
oilisgold
11/2/2021
06:37
Going concern

We have experienced delays commercialising the Genedrive® 96 SARS CoV-2 test and the lack of revenue has impacted our cash position. However we continue to focus on obtaining product approvals and securing sales and we are managing the cost base until revenues are assured. We are confident in our sales forecasts but securing cash generative revenue in the forthcoming months is necessary otherwise the Group will haveto reduce costs and raise additional funds. We continue to adopt a going concern basis for the preparation of the accounts, but the combination of the above factors represents a material uncertainty that may cast significant doubt on the Group and Company's ability to continue as a going concern.

oilisgold
10/2/2021
23:50
In case anyone needs reminding:

"genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter") for its Genedrive(R) 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive's high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory viral samples. The agreement is the result of the collaboration agreement announced in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation in conjunction with its RNAdvance Viral XP extraction kit.

The Genedrive(R) 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument."

aquilla
10/2/2021
23:40
From the LSE site:

"Good news.
Looks like the new fully automated Bio meks are already getting rolled out to help the lab technicians across the USA.
ALSO looks like demand is through the roof!!!
"We put the order in two months before we got it,” she said. “The day after we placed the order, the company told us if we hadn’t ordered it then, we would have had another several months of wait time.
"The whole country is looking for automation"
THE WHOLE COUNTRY
THE WHOLE OF THE USA"

aquilla
Chat Pages: Latest  274  273  272  271  270  269  268  267  266  265  264  263  Older

Your Recent History

Delayed Upgrade Clock